Evidence map›Paper›PMID 29900117›Full record

ArticleEuPA open proteomics2016

Multi-omics "upstream analysis" of regulatory genomic regions helps identifying targets against methotrexate resistance of colon cancer.

Alexander E Kel, Philip Stegmaier, Tagir Valeev, Jeannette Koschmann, Vladimir Poroikov, Olga V Kel-Margoulis, Edgar Wingender

Open access · goldAbstract read
In one paragraph

Article in EuPA open proteomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer.Journal of experimental & clinical cancer research : CR · 2021
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Alexander E KelInstitute of Chemical Biology and Fundamental Medicine, SBRAS, Novosibirsk, Russia.
Philip StegmaiergeneXplain GmbH, D-38302 Wolfenbüttel, Germany.
Tagir ValeevBiosoft.ru, Ltd, Novosibirsk, Russia.
Jeannette KoschmanngeneXplain GmbH, D-38302 Wolfenbüttel, Germany.
Vladimir PoroikovInstitute of Biomedical Chemistry, Moscow, Russia.
Olga V Kel-MargoulisgeneXplain GmbH, D-38302 Wolfenbüttel, Germany.
Edgar WingendergeneXplain GmbH, D-38302 Wolfenbüttel, Germany.
GeneXplain (Germany) · DEInstitute of Biomedical Chemistry · RUInstitute of Chemical Biology and Fundamental Medicine · RUInstitute of Informatics Problems · RUUniversitätsmedizin Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present an "upstream analysis" strategy for causal analysis of multiple "-omics" data. It analyzes promoters using the TRANSFAC database, combines it with an analysis of the upstream signal transduction pathways and identifies master regulators as potential drug targets for a pathological process. We applied this approach to a complex multi-omics data set that contains transcriptomics, proteomics and epigenomics data. We identified the following potential drug targets against induced resistance of cancer cells towards chemotherapy by methotrexate (MTX): TGFalpha, IGFBP7, alpha9-integrin, and the following chemical compounds: zardaverine and divalproex as well as human metabolites such as nicotinamide N-oxide.

Indexed as

ChIP-seqMicroarray dataPathway analysisPromoter analysisProteomics dataUpstream analysis

Identifiers

PMID29900117
PMCPMC5988513
OpenAlexW2520812741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.